Sector News

Valeant grabs a Middle Eastern foothold with $800M pact for Egypt’s Amoun

July 20, 2015
Life sciences
Last month, reports said Valeant was stepping up talks on a deal for one of Egypt’s largest drugmakers. And now, it’s pulled the trigger.
 
The serial buyer has agreed to shell out $800 million on Amoun Pharmaceutical–plus contingent payments, it said in a statement. With that, it’ll grab the leading position in Egypt’s domestic pharma market and gain access to brands in the antihypertensive, broad-spectrum antibiotic and antidiarrheal spaces. Amoun is expecting to hit $223.5 million in sales this year and record a top-line swell of about 20%.
 
But Valeant isn’t expecting to keep its new business confined to Egypt. Rather, the Canadian pharma intends for Amoun to “serve as a platform for further expansion” in the Middle East and North Africa, emerging markets that CEO J. Michael Pearson likes for their speedy growth.
 
Beefing up in developing nations has been on Pearson’s agenda for a while now; it was one perk of the proposed Allergan ($AGN) merger, which Actavis eventually spoiled with a white knight swoop-in late last year. Since then, Valeant has made a pair of other acquisitions, though those–a buyout of North Carolina’s Salix and a pickup of bankrupt Dendreon’s assets–focused on different fast-expanding fields (GI and oncology, respectively).
 
Another burgeoning area Valeant’s long had on its radar? Animal health. Last month, sources told The Wall Street Journal it had approached market leader Zoetis, a company in which former deal partner Bill Ackman’s Pershing Square Capital Management holds a stake.
 
By Carly Helfand
 

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend